Federation Des Caisses Desjardins Du Quebec Spero Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $17.5 Billion
- Q2 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 30 shares of SPRO stock, worth $39. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30
Previous 30
-0.0%
Holding current value
$39
Previous $52,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SPRO
# of Institutions
51Shares Held
15.5MCall Options Held
500Put Options Held
1K-
Anson Funds Management LP Dallas, TX3.75MShares$4.99 Million0.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.77MShares$2.35 Million0.0% of portfolio
-
Atlas Venture Associates Ix, LLC Boston, MA1.35MShares$1.8 Million14.54% of portfolio
-
Acadian Asset Management LLC Boston, MA1.07MShares$1.43 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny976KShares$1.3 Million0.0% of portfolio
About Spero Therapeutics, Inc.
- Ticker SPRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,067,500
- Market Cap $46.6M
- Description
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...